An intravenous agent for neoadjuvant treatment of human epidermal receptor 2 (HER2)-positive locally advanced, inflammatory, or early-stage breast cancer, in combination with trastuzumab and docetaxel.
If you have a Hayes login, click here to view the full report on the Knowledge Center.